ECSP22066680A - Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato - Google Patents

Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato

Info

Publication number
ECSP22066680A
ECSP22066680A ECSENADI202266680A ECDI202266680A ECSP22066680A EC SP22066680 A ECSP22066680 A EC SP22066680A EC SENADI202266680 A ECSENADI202266680 A EC SENADI202266680A EC DI202266680 A ECDI202266680 A EC DI202266680A EC SP22066680 A ECSP22066680 A EC SP22066680A
Authority
EC
Ecuador
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
ECSENADI202266680A
Other languages
English (en)
Inventor
Thomas Goldner
Bertran Jordi Carles Ceron
Helmut Buschmann
Original Assignee
Aic246 Ag Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag Co Kg filed Critical Aic246 Ag Co Kg
Publication of ECSP22066680A publication Critical patent/ECSP22066680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método eficaz para preparar una forma cristalina de trihidrato de sodio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il]acético.
ECSENADI202266680A 2020-02-27 2022-08-24 Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato ECSP22066680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159727 2020-02-27

Publications (1)

Publication Number Publication Date
ECSP22066680A true ECSP22066680A (es) 2022-12-30

Family

ID=69742722

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202266680A ECSP22066680A (es) 2020-02-27 2022-08-24 Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato

Country Status (19)

Country Link
US (1) US20230219899A1 (es)
EP (1) EP4110470A1 (es)
JP (1) JP2023519813A (es)
KR (1) KR20220148863A (es)
CN (1) CN115581118A (es)
AR (1) AR121439A1 (es)
AU (1) AU2021225363B2 (es)
BR (1) BR112022016929A2 (es)
CA (1) CA3169484A1 (es)
CL (1) CL2022002291A1 (es)
CO (1) CO2022012039A2 (es)
CU (1) CU20220049A7 (es)
EC (1) ECSP22066680A (es)
IL (1) IL295795A (es)
MX (1) MX2022010441A (es)
PE (1) PE20230515A1 (es)
TW (1) TW202140453A (es)
UY (1) UY39096A (es)
WO (1) WO2021170874A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
CO2022012039A2 (es) 2022-11-18
EP4110470A1 (en) 2023-01-04
CN115581118A (zh) 2023-01-06
UY39096A (es) 2021-09-30
CU20220049A7 (es) 2023-04-10
IL295795A (en) 2022-10-01
CA3169484A1 (en) 2021-09-02
KR20220148863A (ko) 2022-11-07
AR121439A1 (es) 2022-06-08
CL2022002291A1 (es) 2023-02-03
US20230219899A1 (en) 2023-07-13
MX2022010441A (es) 2022-10-18
TW202140453A (zh) 2021-11-01
WO2021170874A1 (en) 2021-09-02
PE20230515A1 (es) 2023-03-24
AU2021225363A1 (en) 2022-10-13
BR112022016929A2 (pt) 2022-12-06
AU2021225363B2 (en) 2024-09-19
JP2023519813A (ja) 2023-05-15

Similar Documents

Publication Publication Date Title
RU2397976C2 (ru) Производные бензамидов и гетероаренов
ES2485825T3 (es) Intermedio de rosuvastatina cálcica y método de preparación del mismo
AR084639A1 (es) Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo
CO2019011578A2 (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo
DOP2014000286A (es) Compuestos de acido dimetil-benzoico
BR112015000160A2 (pt) fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético
PE20121518A1 (es) Bloqueantes de los canales de sodio dependientes de voltaje
EA201490650A1 (ru) Фармацевтические композиции
RU2012131341A (ru) Индол-пиперидинилбензиламины как ингибиторы бета-триптазы
CO2021011836A2 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
ES2603227T3 (es) Proceso para la preparación de compuestos cetólidos
MX2022001958A (es) Sal.
EA202190880A1 (ru) Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение
CU24667B1 (es) Derivados de aril-n-arilo para el tratamiento de una infección por virus de ácido ribonucleico (arn)
ES2555139T3 (es) Nuevo procedimiento para la preparación de Linezolid y sus nuevos intermedios
ECSP22066680A (es) Un método para producir una forma cristalina de 2-[(4s)-8- fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato
UY32295A (es) Dihidroetorfina
EA202192731A1 (ru) СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
PE20141385A1 (es) Bloqueantes de los canales de sodio dependientes de voltaje
EA201270653A1 (ru) Антагонист dpи его применение
RU2009147291A (ru) Применение ингибиторов raf для лечения рака щитовидной железы
JP2016520090A5 (es)
MX2019003457A (es) Enantiómero de ácido fenilpropiónico sustituido y método de fabricación, composición, y aplicación del mismo.
WO2016051422A3 (en) Process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide and its polymorphs thereof